ArticleNature biomedical engineering2025
Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading.
Abstract read
In one paragraph
Article in Nature biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy.Materials today. Bio · 2026Article
- SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.Journal for immunotherapy of cancer · 2026Article
- An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.EBioMedicine · 2026Article
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.Journal for immunotherapy of cancer · 2026Article
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- Novel Organelle-Based Intracellular Immunity with Mechanistic and Therapeutic Implications.Barrier immunity · 2026Article
- Deciphering the tumor microenvironment and role of immunotherapy in diffuse midline glioma: A scoping review.Neuro-oncology · 2026Article
- Review
- Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy.Asian journal of pharmaceutical sciences · 2026Review
- After a Decade of Therapy Revolution in Cutaneous Melanoma-Perspectives on Emerging Treatment Strategies.Oncology research · 2026Review
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future.International journal of molecular sciences · 2025Review
- Review
- Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival in a pandemic.medRxiv : the preprint server for health sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Sadeem Qdaisat *Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Brandon Wummer *Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Brian D Stover *Department of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Dingpeng ZhangLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
James McGuinessLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Frances WeidertLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Jonathan Chardon-RoblesLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Adam GrippinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anna DeVriesLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Chong ZhaoLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Christiano MarconiLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Aida KarachiLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Chao XieLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Gabriel JobinDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Ruixuan LiuLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Stephen MichelLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Xiaojie MaDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Rachel S F MoorLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-2787-4317
Christina von RoemelingLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Duy T NguyenDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-3204-7279
Leighton ElliottDepartment of Medicine, Division of Hematology and Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-3616-849X
Nagheme ThomasLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Arnav BarpujariDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Hilary GeffrardLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Yodarlynis CampaneriaLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Elizabeth Ogando-RivasLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Cathleen RabideauDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Dhruvkumar SoniLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Jianping HuangLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Sheila Carrera-JustizCollege of Veterinary Medicine, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-6345-5921
Kristianna FredenburgDepartment of Pathology, University of Florida, Gainesville, FL, USA.
Natalie L SilverCenter of Immunotherapy and Precision Immuno-Oncology/Head and Neck Institute, Cleveland Clinic, Cleveland, OH, USA.
W Gregory SawyerDepartment of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-4461-7227
Maryam RahmanLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
John A LigonDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-5513-1233
Catherine T FloresLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Ji-Hyun LeeDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-6420-5150
Duane A MitchellLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Paul CastilloDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.
Hector R Mendez-GomezLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-7493-5365
Elias J SayourLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. Elias.Sayour@neurosurgery.ufl.edu.ORCID http://orcid.org/0000-0002-5309-3197
Funding
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomasR37CA251978 · NCI · UNIVERSITY OF FLORIDA · PI Elias Sayour · 2021 to 2026
$3.4MOvercoming metastatic spread of osteosarcoma with RNA loaded nanoparticlesR01CA266857 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2022 to 2025
$2.9MHarnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting GlioblastomaK08CA199224 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2016 to 2020
$791kFDA HHS R01 FD007268NCI NIH HHS K08 CA199224NCI NIH HHS R01 CA266857NCI NIH HHS R37 CA251978U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266857U.S. Department of Health & Human Services | U.S. Food and Drug Administration (U.S. Food & Drug Administration) R01FD007268
Abstract
The success of cancer immunotherapies is predicated on the targeting of highly expressed neoepitopes, which preferentially favours malignancies with high mutational burden. Here we show that early responses by type-I interferons mediate the success of immune checkpoint inhibitors as well as epitope spreading in poorly immunogenic tumours and that these interferon responses can be enhanced via systemic administration of lipid particles loaded with RNA coding for tumour-unspecific antigens. In mice, the immune responses of tumours sensitive to checkpoint inhibitors were transferable to resistant tumours and resulted in heightened immunity with antigenic spreading that protected the animals from tumour rechallenge. Our findings show that the resistance of tumours to immunotherapy is dictated by the absence of a damage response, which can be restored by boosting early type-I interferon responses to enable epitope spreading and self-amplifying responses in treatment-refractory tumours.
Indexed as
EpitopesImmunotherapyInterferon Type INeoplasmsAnimalsAntigens, NeoplasmCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsMiceMice, Inbred C57BLAntigens, NeoplasmEpitopesImmune Checkpoint InhibitorsInterferon Type I
Identifiers
PMID
40681861What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.